Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability

P D Cani, S Possemiers, T Van de Wiele, Y Guiot, A Everard, O Rottier, L Geurts, D Naslain, A Neyrinck, D M Lambert, G G Muccioli and N M Delzenne

*Gut* 2009;58;1091-1103; originally published online 24 Feb 2009;
doi:10.1136/gut.2008.165886

Updated information and services can be found at:
http://gut.bmj.com/cgi/content/full/58/8/1091

These include:

**References**

This article cites 84 articles, 33 of which can be accessed free at:
http://gut.bmj.com/cgi/content/full/58/8/1091#BIBL

1 online articles that cite this article can be accessed at:
http://gut.bmj.com/cgi/content/full/58/8/1091#otherarticles

**Open Access**

This article is free to access

**Email alerting service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

**Topic collections**

Articles on similar topics can be found in the following collections

*Unlocked* (147 articles)

**Notes**

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to *Gut* go to:
http://journals.bmj.com/subscriptions/
Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability

P D Cani,¹ S Possemiers,² T Van de Wiele,² Y Guiot,³ A Everard,¹ O Rottier,¹ L Geurts,¹ D Naslain,¹,4 A Neyrinck,¹ D M Lambert,⁴ G G Muccioli,⁵ N M Delzenne¹

ABSTRACT

Background and aims: Obese and diabetic mice display enhanced intestinal permeability and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our recent data support the idea that a selective increase of Bifidobacterium spp. reduces the impact of high-fat diet-induced metabolic endotoxaemia and inflammatory disorders. Here, we hypothesised that prebiotic modulation of gut microbiota lowers intestinal permeability, by a mechanism involving glucagon-like peptide-2 (GLP-2) thereby improving inflammation and metabolic disorders during obesity and diabetes.

Methods: Study 1: ob/ob mice (Ob-CT) were treated with either prebiotic (Ob-Pre) or non-prebiotic carbohydrates as control (Ob-Cell). Study 2: Ob-CT and Ob-Pre mice were treated with GLP-2 antagonist or saline. Study 3: Ob-CT mice were treated with a GLP-2 agonist or saline. We assessed changes in the gut microbiota, intestinal permeability, gut peptides, intestinal epithelial tight-junction proteins ZO-1 and occludin (qPCR and immunohistochemistry), hepatic and systemic inflammation.

Results: Prebiotic-treated mice exhibited a lower plasma lipopolysaccharide (LPS) and cytokines, and a decreased hepatic expression of inflammatory and oxidative stress markers. This decreased inflammatory tone was associated with a lower intestinal permeability and improved tight-junction integrity compared to controls. Prebiotic increased the endogenous intestinotrophic proglucagon-derived peptide (GLP-2) production whereas the GLP-2 antagonist abolished most of the prebiotic effects. Finally, pharmacological GLP-2 treatment decreased gut permeability, systemic and hepatic inflammatory phenotype associated with obesity to a similar extent as that observed following prebiotic-induced changes in gut microbiota.

Conclusion: We found that a selective gut microbiota change controls and increases endogenous GLP-2 production, and consequently improves gut barrier functions by a GLP-2-dependent mechanism, contributing to the improvement of gut barrier functions during obesity and diabetes.

Obesity is typically associated with a cluster of several metabolic disorders, characterised by a low-grade inflammation.¹ ² Evidence that the gut microbiota composition can be different between healthy and obese and/or type 2 diabetic patients has led to the investigation of this environmental element as a key factor in the pathophysiology of metabolic diseases.³ ⁶

We previously reported that the gut microbiota is involved in high-fat diet-induced metabolic endotoxaemia, adipose tissue inflammation and metabolic disorders.⁶ ⁷ The link between high-fat diet-induced inflammation, oxidative stress, metabolic disorders, and gut microbiota, could be lipopolysaccharide (LPS)-dependent.⁷ ¹⁰–¹⁴ Several pieces of clinical and experimental data have confirmed that LPS significantly contributes to the development of obesity-related inflammatory liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.¹⁵–¹⁷ High plasma LPS levels could result from an increased production of endotoxin upon changes in the gut microbiota.⁵ ⁸ Normally, the intestinal epithelium acts as a continuous barrier to avoid LPS translocation; yet some endogenous or exogenous events may alter this protective function. Among the elements promoting a leaky gut, and thus an increased plasmatic LPS level, are alcohol consumption,¹⁹ ²⁰–²² immobilisation stress,²³ ²⁴ and radiation²⁵ have been proposed. In addition, we have recently shown that the modulation of gut bacteria following a high-fat diet strongly increases intestinal permeability, by reducing the expression of genes coding for two tight junction proteins ZO-1 and occludin.⁶ We previously reported that gut bacteria are clearly involved in these events since obese and high-fat fed-diabetic mice treated with an antibiotic recovered normal intestinal epithelial integrity.⁶ Also, recent data have shown that obese and diabetic mice display enhanced intestinal permeability, and are characterised by a metabolic endotoxaemia and a low-grade inflammation.⁶ ⁷ ²⁶ Furthermore, high-fat feeding changes gut microbiota⁶ ⁸ ²⁷ towards a decreased number of bifidobacteria,⁶ ⁸ a group of bacteria which has been shown to reduce intestinal LPS levels in mice and to improve the mucosal barrier function.²⁸–³² Besides, we have shown that feeding mice with prebiotics increased the number of intestinal bifidobacteria and reduced the impact of high-fat diet-induced metabolic endotoxaemia and inflammatory disorders.⁸ ³⁵ Importantly, however, the mechanisms linking prebiotic-induced changes in gut microbiota, metabolic endotoxaemia and the improvement of obesity-related hepatic and metabolic disorders are still unknown.

By using these experiments, we have tested the hypothesis that the control of gut permeability through the selective modulation of gut microbiota by prebiotics participates in the improvement of metabolic diseases in ob/ob mice. Novel mechanisms involving the influence of gut fermentation
on specific proglucagon-derived peptides – namely, glucagon-like peptide-2 (GLP-2) – are proposed.

**MATERIALS AND METHODS**

**Animals**

**Experiment 1**

Six-week-old ob/ob (n = 10/group) mice (C57BL/6 background; Jackson Laboratory, Bar Harbor, Maine, USA) were housed in a controlled environment (12 h daylight cycle, lights off at 18:00 hours) in groups of 2 mice/cage, and kept with free access to food and water. The mice were fed a control diet (Ob-CT) (A04, Villemoisson-sur-Orge, France), or a control diet containing a mix of a fermentable dietary fibre (oligofructose) (Ob-Pre) (Orafti, Tienen, Belgium), or a diet containing a mix of a non-fermentable dietary fibre (microcrystalline cellulose) (Ob-Cell) (Vivapur Microcrystalline cellulose; J. Retten Maier 38 Söhne, Weissenborn, Germany). Dietary fibres were added in a proportion of 9:1 (weight of control diet:weight of fibres).

**Experiment 2**

Six-week-old ob/ob (n = 8/group) mice (C57BL/6 background; Jackson Laboratory) were housed in a controlled environment (12 h daylight cycle, lights off at 18.00 hours) in groups of 2 mice/cage, and kept with free access to food and water. To study the significance of GLP-2 in this model, mice were injected subcutaneously twice daily for 4 weeks with 2.5 μg/kg of GLP-2 receptor antagonist GLP-2 (3–33) (Eurorgenec, Verviers, Belgium) as described or saline. The mice were fed a control diet and injected with saline or GLP-2 antagonist (Ob-CT and Ob-Ant, respectively), or fed the prebiotic diet and injected with saline or GLP-2 antagonist (Ob-Pre and Ob-Pre-Ant, respectively).

**Experiment 3**

Six-week-old ob/ob (n = 6/group) mice (C57BL/6 background; Jackson Laboratory) were housed in a controlled environment (12 h daylight cycle, lights off at 1800 hours) in groups of 2 mice/cage, and kept with free access to food and water. The mice were fed the same control diet as described in experiment 1. The mice were separated into two groups and injected subcutaneously twice daily for 12 days with 25 μg GLP-2 (1–35) (Bachem, Bubendorf, Switzerland) (Ob-GLP-2), or saline (Ob-CT). GLP-2 doses were based on previous studies describing the physiological effects (ie, the intestinotrophic properties) of the peptides.

**Tissue sampling**

Mice were anaesthetised (ketamine/xylazine, intraperineally, 100 and 10 mg/kg, respectively) after a 5 h period of fasting, and blood samples and tissues were harvested for further analysis. Mice were killed by cervical dislocation. Liver, caecum (full and empty), muscles (vastus lateralis), and adipose tissues (epidymal, subcutaneous and visceral) were precisely dissected and weighed. The intestinal segments (jejunum, colon) were immersed in liquid nitrogen, and stored at −80°C, for further analysis.

**Microbial analysis of the caecal content of selected mice**

Metagenomic DNA was extracted from the caecal content of randomly selected mice (5/group), using the QIAamp DNA stool mini kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions. Denaturing gradient gel electrophoresis (DGGE) on total bacteria, bifidobacteria and lactobacilli were performed to study the qualitative effect of the treatment on the structure and composition of the intestinal microbial community. DGGE with a 45–60% denaturant gradient were used to separate the polymerase chain reaction (PCR) products obtained with a nested approach for the 16S rDNA genes of bifidobacteria (primers BIF1684-F/BIF6602r) and lactobacilli (SGLAB0108F-SGLAB0667). The first PCR round was followed by a second amplification with primers 338F-GC and 518R. The latter primers were also used to amplify the 16S rDNA of all bacteria on total extracted DNA. The DGGE patterns obtained were subsequently analysed using the Bionumerics software version 2.0 (Applied Maths, Sint-Martens-Latem, Belgium). In brief, the calculation of the similarities was based on the Pearson (product–moment) correlation coefficient. Clustering analysis was performed using the unweighted pair group method with arithmetic mean clustering algorithm (UPGMA) to calculate the dendrograms of each DGGE gel and a combination of all gels. The latter was performed on a created composite dataset. Multidimensional scaling (MDS) analysis was used to reduce the different data of the complex DGGE patterns of one sample to one point in a three-dimensional space. MDS was based on the combined information from the distance matrices of each DGGE, obtained using similarity coefficients (Pearson correlation).

**Quantitative PCR (qPCR)**

Total RNA from tissues was prepared using the TRIpure reagent (Roche, Basel, Switzerland) as described. cDNA was synthesised using a reverse transcription kit (Promega, Madison, Wisconsin, USA) from 1 μg of total RNA. qPCR was performed with a STEP one PLUS instrument and software (Applied Biosystems, Foster City, California, USA), as described. Primer sequences for the targeted mouse genes are presented in supplemental table 1.

**Real-time qPCR**

Total RNA from tissues was prepared using the TRIpure reagent (Roche, Basel, Switzerland) as described. cDNA was synthesised using a reverse transcription kit (Promega, Madison, Wisconsin, USA) from 1 μg of total RNA. qPCR was performed with a STEP one PLUS instrument and software (Applied Biosystems, Foster City, California, USA), as described. Primer sequences for the targeted mouse genes are presented in supplemental table 1.

**Immunofluorescence analysis of occludin and ZO-1**

Jejunum segments were immediately removed, washed with PBS, mounted in embedding medium (Tissue-Tek, Sakura, Netherlands), and stored at −80°C until use. Cryosections (5 μm) were fixed in acetone at −20°C for 5 min for occludin and fixed in ethanol for 30 min at room temperature and in acetone at −20°C for 5 min for ZO-1. Non-specific background was blocked by incubation with 10% bovine serum albumin (BSA) in Tris-buffered saline (TBS) and 0.3% Triton X-100 (50 min at room temperature). Sections were incubated with rabbit anti-occludin or rabbit anti-ZO-1 (1:400 for ZO-1 and 1:100 for occludin staining; Zymed Laboratories, San Francisco, California, USA) for 2 h. Sections were washed three times for 10 min in TBS and probed with goat anti-rabbit fluorescein isothiocyanate (FITC)-conjugated antibodies (1:50, Zymax; Zymed Laboratories). Slides were washed three times for 10 min in TBS and mounted in mounting medium (Vectorshield; Vector Laboratories, Burlingame, California, USA). Sections were visualised on a fluorescence microscope using a x40 objective, and images were stored digitally with Leica software. As a control, slides were incubated with serial dilutions of the primary antibody to signal extinction. Two negative controls were used: slides incubated with irrelevant
antibody or without primary antibody. All the stainings were performed in duplicate in non-seral distant sections, and analysed in a double-blind manner by two different investigators.

**Intestinal permeability in vivo**
This measure is based on the intestinal permeability towards 4000 Da fluorescent dextran–FITC (DX-4000–FITC) (FD4000; Sigma-Aldrich, St. Louis, Missouri, USA) as described. Briefly, mice that had fasted for 6 h were given DX-4000–FITC by gavage (500 mg/kg body weight, 125 mg/ml). After 1 h and 4 h, 120 μl of blood was collected from the tip of the tail vein. The blood was centrifuged at 4°C, 12 000 g for 5 min. Plasma was diluted in an equal volume of PBS (pH 7.4) and analysed for DX-4000–FITC concentration with a fluorescence spectrophotometer (HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley, Massachusetts, USA), or a mouse gut hormones panel in duplicate by using a Bio-Plex Multiplex kit (Bio-Rad, Nazareth, Belgium), or a mouse gut hormones panel (Luminex technology (Bio-Rad Bioplex; Bio-Rad) following the manufacturer’s instructions, an EIA kit (GLP-2 EIA kit) (Yanaihara Institute, Shizuoka, Japan) was used to quantify GLP-2.

**Biochemical analyses**
Plasma LPS concentration was determined by using a kit based upon a Limulus amoebocyte extract (LAL kit endpoint-QCL1000; Cambrex BioScience, Walkersville, Maryland, USA), samples were diluted 1/40 to 1/100 and heated for 20 cycles of 10 min at 65°C and 10 min at 4°C. An internal control for LPS recovery was included in the calculation. Plasma cytokines (interleukin (IL) 1α, IL1β, tumour necrosis factor (TNF) α, IL6, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, IL10, interferon (INF) γ, IL15, IL18) and gut hormones (GLP-1 (active), GIP (total), amylin (active), pancreatic polypeptide) were respectively determined in duplicate by using a Bio-Plex Multiplex kit (Bio-Rad, Nazareth, Belgium), or a mouse gut hormones panel (LincoPlex; Millipore, Brussels, Belgium), and measured by using Luminex technology (Bio-Rad Bioplex; Bio-Rad) following the manufacturer’s instructions, an EIA kit (GLP-2 EIA kit) (Yanaihara Institute, Shizuoka, Japan) was used to quantify GLP-2.

**Statistical analysis**
Results are presented as mean with the SEM. The statistical significance of differences was analysed by one-way ANOVA followed by post hoc Bonferroni’s multiple comparison test or Kruskal–Wallis for non-parametric data followed by Dunn’s multiple comparison test. Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. Comparisons between GLP-2-treated mice and control mice were performed using the two-tailed Student t test. Multiple correlation analyses were assessed by the Pearson’s test using GraphPad Prism version 5.00 for windows. Results were considered statistically significant when p<0.05.

### RESULTS

**Prebiotic treatment induces changes in the gut microbiota of ob/ob mice**
Feeding ob/ob mice with the prebiotic carbohydrates (Ob-Pre) induced significant changes in the gut microbiota of the caecum, with a higher total bacteria count, Lactobacillus spp., *Bifidobacterium* spp., and the *Clostridium coccoide–Eubacterium rectale* cluster (table 1), as compared to the control mice (Ob-CT and Ob-Cell).

<table>
<thead>
<tr>
<th>Bacterial content</th>
<th>Ob-CT</th>
<th>Ob-Cell</th>
<th>Ob-Pre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bacteria</td>
<td>5.74±(2.05)</td>
<td>4.30±(0.38)</td>
<td>8.07±(1.05)</td>
</tr>
<tr>
<td><em>Bifidobacterium</em> spp</td>
<td>4.65±(1.58)</td>
<td>3.38±(0.37)</td>
<td>6.35±(1.10)</td>
</tr>
<tr>
<td><em>Lactobacillus</em> spp</td>
<td>4.93±(1.76)</td>
<td>3.79±(0.38)</td>
<td>7.18±(1.40)</td>
</tr>
<tr>
<td><em>Clostridium</em> coccoide–<em>Eubacterium rectale</em> cluster</td>
<td>3.65±(1.37)</td>
<td>2.72±(0.20)</td>
<td>6.41±(1.27)</td>
</tr>
</tbody>
</table>

Results are given as the log DNA copies/caecal content (SD). Data are mean with the SD.

| Data with different superscript letters are significantly different p<0.05, according to the post hoc ANOVA statistical analysis. **CT, Cell and Pre, respectively, refer to the selected ob/ob mice fed a normal-diet, non-prebiotic control diet or prebiotic diet.**

Changes in the gut microbiota upon prebiotic administration reduce intestinal permeability
Ob-Pre fed mice exhibited a 3-fold lower plasma DX-4000–FITC area under the curve (fig 2A) as compared to Ob-CT and Ob-Cell mice. In accordance with the in vivo assessment of intestinal permeability, LPS levels were significantly lower in Ob-Pre mice plasma samples, as compared to the other groups (fig 2B). Moreover, plasma DX-4000–FITC and portal plasma LPS levels were positively and significantly correlated (fig 2B, inset), further confirming the relation between intestinal permeability and the development of metabolic endotoxaemia. Gut permeability is controlled by several specific tight-junction proteins. Among these, ZO-1 and occludin have been proposed as key markers of tight-junction integrity. The prebiotic treatment increased ZO-1 and occludin mRNA in the jejunum as key markers of tight-junction integrity. 26 The prebiotic treatment induced important changes in the gut microbiota of the Ob-Pre mice compared to the control groups."
Inflammatory bowel disease

Figure 1 Prebiotic-associated changes in the gut microbiota. DGGE fingerprint patterns of the caecal microbial community of selected ob/ob mice fed a normal-diet (Ob-CT, white symbols), non-prebiotic control diet (Ob-Cell, grey symbols) or prebiotic diet (Ob-Pre, black symbols) for 5 weeks. The DGGE profiles were constructed using primers for (A) Total bacteria (B) Bifidobacterium spp (C) Lactobacillus spp. Cluster analysis is based on the Pearson product–moment correlation coefficient and UPGMA linkage. (D) Three-dimensional multidimensional scaling analysis conducted on the DGGE fingerprinting composite data set (total bacteria, Bifidobacterium spp. and Lactobacillus spp.). CT, Cell and Pre respectively refer to the selected ob/ob mice fed a normal-diet, non-prebiotic control diet or prebiotic diet for 5 weeks. DGGE, denaturing gradient gel electrophoresis; UPGMA, unweighted pair group method with arithmetic mean clustering algorithm.

score analysis confirmed the strong alteration of ZO-1 and occludin distribution and expression as compared to wild-type mice (fig 2E,H). In accordance with the mRNA analysis, prebiotic feeding improved the tight junctions, since the immunohistochemical staining of both proteins localised along the apical cellular border was higher in Ob-Pre as compared to Ob-CT and Ob-Cell mice (fig 3A,B).

To identify whether the changes in the gut microbiota and tight-junction protein expression are associated with in vivo gut permeability, multiple correlation analysis between these parameters was performed. Indeed, a negative correlation between tight-junction proteins mRNA and plasma DX-4000–FITC was found in the jejunum segment (fig 2D,G), and in the colon (supplementary data 1). In addition, the caecal content of Bifidobacterium spp. and portal plasma levels of LPS showed a negative correlation (supplementary data 1), suggesting that the specific increase of bifidobacteria positively impacted the development of metabolic endotoxaemia.

Changes in the gut microbiota upon prebiotic administration are associated with improved systemic and hepatic inflammation

To study the effects of changes in the gut microbiota and improved barrier function on the one hand, and metabolic disorders on the other hand, we first assessed systemic inflammation. All plasma cytokine and chemokine concentrations were decreased in Ob-Pre mice when compared to Ob-CT and Ob-Cell mice (fig 4). Metabolic endotoxaemia is frequently associated with hepatic inflammation, and with increased oxidative stress driving metabolic disorders. Here we found that changing the gut microbiota significantly reduced plasminogen activator inhibitor 1 (PAI-1), CD68, NADPH oxidase (NADPHox) and inducible nitric oxide synthase (iNOS) mRNA concentrations (fig 5A,B,E,F), and tended to decrease toll-like receptor 4 (TLR4) and TNFα mRNA concentrations (fig 5I,J). The oxidative stress marker NADPHox positively correlated with macrophage infiltration markers (CD68, TLR4) (fig 5C,D). Moreover, both macrophage infiltration markers were correlated (fig 5G). Plasma chemokine MCP-1 positively correlated with tissue macrophages infiltration and oxidative stress markers (fig 5H,K,L). Accordingly, plasma LPS levels were positively correlated with NADPHox and macrophage infiltration markers (liver CD68 mRNA and plasma MCP-1 levels) (supplemental data 1). Furthermore, we found that these markers were negatively correlated with the content of Bifidobacterium spp. (supplemental data 1). The lower inflammatory and oxidative stress was associated with a lower total hepatic lipid content (Ob-CT: 839 a (SEM 111); Ob-Cell: 781 b (SEM 42); Ob-Pre: 531 b (SEM 58) mg of lipids/liver, Ob-Pre p<0.05 vs Ob-CT and Ob-Cell) and confirmed by histological analysis (not shown). (Different superscript letters denote a statistical difference between the groups.) Altogether, these multiple correlations support a strong relationship between gut microbiota, gut permeability, systemic and hepatic inflammation, oxidative stress and macrophage infiltration in ob/ob mice.

Prebiotic feeding modulates plasma gut peptides and adiposity

Prebiotic administration decreased food intake (Ob-CT: 24.9 a (SEM 0.7); Ob-Cell: 20.0 b (SEM 0.5); Ob-Pre: 16.5 c (SEM 1.1) kcal/day.mice; p<0.05). We have previously demonstrated that prebiotic-induced changes in the gut microbiota modulate gastrointestinal peptides (GLP-1, peptide YY (PYY),...
ghrelin) involved in glucose homeostasis, appetite and/or body weight regulation. Here, we found that the prebiotic treatment also modulated portal plasma gut peptides in ob/ob mice, leading to a significant increase in GLP-1 (table 2). In addition, the glucose-dependent insulinotropic polypeptides (GIPs), another peptide associated with the development of obesity, diabetes and adiposity, was significantly decreased (table 2). In accordance with this, Ob-Pre mice had lower visceral, epididymal and subcutaneous adipose depots and a higher muscle mass as compared to the other groups (supplementary data 2).

This study is the first in which it is shown that, besides an effect on gut peptides, feeding prebiotics also modulated two pancreatic peptides, since it significantly increased amylin (table 2) and decreased pancreatic polypeptide (PP) as compared to Ob-CT and Ob-Cell mice (table 2). The link between the above-mentioned peptides modulated by prebiotics and gut permeability has not been described so far. Moreover, the decrease in food intake and/or a decrease in adiposity are not involved in changes in gut permeability. Thus, we have hypothesised that GLP-2, a peptide clearly related to GLP-1 production, could link changes in gut microbiota and intestinal barrier function.

Prebiotic administration increases intestinal proglucagon mRNA and portal plasma proglucagon-derived peptide GLP-2

We and other have previously shown that changing gut microbiota by using fermentable non-digestible carbohydrate significantly increases gut weight and promotes proliferation of epithelial cells.52-54 In previous studies, the increase in GLP-1 plasma level was associated with a higher GPL-1 peptide and proglucagon mRNA expression in the (proximal) colon tissue. Interestingly, our study is the first to show that a
higher proglucagon mRNA content occurs in the proximal colon – as expected – and also in the jejunum (fig 6A,B). Among the proglucagon-derived peptides, GLP-2 is co-secreted with GLP-1 and exerts an intestinotrophic effect.\textsuperscript{39,57,58} GLP-2 enhances intestinal epithelial proliferation and reduces gut permeability,\textsuperscript{59–62} hence, we found that Ob-Pre fed mice exhibited a significant increase of plasma GLP-2 levels (table 2). Importantly, portal plasma GLP-2 and both plasma markers of gut permeability (DX-4000–FITC and LPS) were negatively correlated (fig 6C,D). Along the same line, intestinal proglucagon and tight-junction mRNA (ZO-1, occludin) were positively correlated (fig 6E,F). Altogether, these data suggest that the prebiotic-induced intestinal proglucagon mRNA enhanced expression and the consequent GLP-2 production indicate that this peptide may positively impacts on gut barrier integrity.

**Chronic GLP-2 antagonist treatment blunts prebiotic-induced reduction in endotoxaemia and hepatic inflammatory tone**

To causally link changes in endogenous GLP-2 production upon prebiotic treatment with the improvement of metabolic endotoxaemia, and inflammatory markers, we chronically blocked GLP-2 receptor in prebiotic fed ob/ob mice by using GLP-2 antagonist. In this second set of experiments, we confirm the data observed in the first study showing that prebiotic-induced changes in gut microbiota are linked to a significant decrease in plasma LPS levels, hepatic inflammation and oxidative stress markers such as PAI-1, CD68, NADPHox and TLR4 mRNA concentrations (fig 7B–D,F), and to a tendency to decrease for iNOS and TNF\textsubscript{a} mRNA concentrations (fig 7E,G). In addition, we also confirm that the prebiotic treatment increases ZO-1 and

**Figure 3** Prebiotic treatment changes tight-junction proteins distribution. Representative immunofluorescence staining for (A) ZO-1 and (B) occludin in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell), prebiotic diet (Ob-Pre) for 5 weeks. WT, wild-type.

**Figure 4** Prebiotic treatment reduces the occurrence of systemic inflammation. (A) IL1\textsubscript{a}, (B) IL1\textsubscript{b}, (C) TNF\textsubscript{a}, (D) MCP-1, (E) MIP-1\textsubscript{a}, (F) INF\textsubscript{\gamma}, (G) IL6, (H) IL10, (I) IL18 and (J) IL15 plasma levels (pg/ml) in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell) or prebiotic diet (Ob-Pre) for 5 weeks. Data are mean with the SEM. Data with different superscript letters are significantly different (p<0.05), according to the post hoc ANOVA statistical analysis. IFN, interferon; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; MIP-1\textsubscript{a}, macrophage inflammatory protein-1a; TNF, tumour necrosis factor.
occludin mRNA (fig 7H) and the GLP-2 precursor transcript (proglucagon mRNA) content in the jejunum (fig 7I). Importantly, the GLP-2 antagonist completely blunts the prebiotic-induced reduction in endotoxaemia (fig 7A). Hence, most of the prebiotic-induced changes of hepatic inflammation and oxidative stress markers are also controlled by a GLP-2-dependent mechanism. We observed that mice treated concomitantly with the prebiotic and the GLP-2 antagonist or GLP-2 antagonist alone exhibit CD68, NADPHox and TLR4 mRNA levels (fig 7B–D) similar to the control mice, except for the PAI-1 mRNA levels (fig 7F) which remain equivalent to the prebiotic treated mice with or without GLP-2 antagonist treatment. Moreover, GLP-2 antagonist treatment completely blocked the enhanced proglucagon, ZO1 and occludin mRNA levels found in prebiotic fed mice that reach values similar to the control (fig 7H,I).

Chronic GLP-2 pharmacological treatment lowers endotoxaemia, improves gut permeability markers, and reduces systemic and hepatic inflammation, oxidative stress and macrophage infiltration markers

To study the impact of a pharmacological GLP-2 treatment, without modulation of the gut microbiota, we treated ob/ob mice with GLP-2 for 12 days. Body weight, food intake, adiposity, liver weight were equivalent between Ob-CT mice and Ob-GLP-2 mice (supplemental data 3).

Importantly, we demonstrated that GLP-2 administration to ob/ob mice dramatically decreased plasma LPS by about 50% (fig 8A). This was accompanied by a lower plasma inflammatory tone (IL1α, MIP-1α, MCP-1, IL10) (fig 8B–E). Furthermore, as reported in both prebiotics-fed mice studies, mRNA concentrations of macrophage infiltration (TLR4, CD68) (fig 8G,I), inflammation (TNFα, PAI-1) (fig 8F,J) and oxidative stress (iNOS, NADPHox) markers (fig 8H,K) were decreased in Ob-GLP-2 mice as compared to Ob-CT mice. Finally, ZO-1 and occludin staining immunohistochemical score analysis confirmed the strong impact of GLP-2 on the tight-junctions proteins (fig 8L). In accordance with the prebiotic effect, the immunohistochemical staining of both proteins localised along the apical cellular border was higher in Ob-GLP-2 as compared to Ob-CT (fig 8M).

Therefore, the gut peptide GLP-2 appears as a credible link between gut microbiota, gut permeability, and inflammatory tone.

DISCUSSION

Several reports have demonstrated that the gut microbiota participates in the development of obesity by several mechanisms, ie, by harvesting energy from the diet, by modulating the gut microbiota control hepatic inflammation, oxidative stress and macrophage infiltration markers. (A,I) Inflammation: PAI-1, TNFα mRNA concentrations; (B,J) Macrophage infiltration markers: CD68, TLR4 mRNA concentrations; (E,F) Oxidative stress markers: NADPHox, iNOS mRNA concentrations in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell) or prebiotic diet (Ob-Pre) for 5 weeks. Data are mean with the SEM. Data with different superscript letters are significantly different (p<0.05), according to the post hoc ANOVA statistical analysis. Correlations between liver NADPHox mRNA and (C) liver CD68 mRNA, (D) TLR4 mRNA levels or (K) plasma MCP-1 levels. Correlations between plasma MCP-1 and (H) liver CD68 mRNA or (L) TLR4 mRNA. (G) Correlation between liver CD68 mRNA and TLR4 mRNA concentrations (p<0.05) the inset corresponds to Pearson’s r correlation and corresponding p value. iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemotactrant protein-1; NADPHox, NADPH oxidase; PAI-1, plasminogen activator inhibitor; TLR, toll-like receptor; TNF, tumour necrosis factor.
synthesis of gut peptides involved in energy homeostasis, and/or by regulating fat storage. We have recently demonstrated that mice fed a high-fat diet were characterised by an increase in gut permeability and metabolic endotoxaemia. The inflammatory phenotype of \textit{ob/ob} mice originates from the gut microbiota, since changing the gut microbiota using antibiotics lowers endotoxaemia-induced inflammation and metabolic disorders. Recently, it has been proposed that this higher endotoxaemia in \textit{ob/ob} and \textit{db/db} mice was dependent on a disruption of the key tight-junction proteins, ZO-1 and occludin. Here we confirm that obese mice exhibit an altered gut barrier, characterised by a disruption of tight-junction proteins. Among the mechanisms involved in this phenomenon, excessive TNF$\alpha$ production was proposed to help propagate the extension of a local or systemic inflammation and this inflammatory process per se would trigger the alteration of both junctional proteins. Our data show that prebiotic-fed mice have a lower level of several plasma cytokines well-known to promote tight-junction disruption such as TNF$\alpha$, IL1b, IL1$\alpha$, IL6, INF$\gamma$. In addition, we also found a significant decrease of the chemokines MCP-1 and MIP-1a.

In the present study, we demonstrated, in two separate set of experiments, that changing gut microbiota of \textit{ob/ob} mice in favour of the \textit{Bifidobacterium} spp. is associated with a significant improvement of gut permeability measured in vivo; this phenomenon was linked to an increase in tight-junction mRNA expression and proteins distribution. The improved gut barrier observed in prebiotic-fed mice was correlated to the lower portal plasma LPS levels and inflammatory tone (ie, decrease in circulating cytokines). The leakage of gut microbiota-derived LPS into the portal blood is a well-established mechanism of metabolic endotoxaemia that triggers liver inflammation and oxidative stress. In the present studies, we found that lowering systemic inflammation by prebiotics is significantly correlated with a strong decrease in markers of oxidative and inflammatory stress in the liver tissue. Altogether,

### Table 2

<table>
<thead>
<tr>
<th>Gut peptide</th>
<th>Ob-CT</th>
<th>Ob-Cell</th>
<th>Ob-Pre</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLP-1 (active) (pmol/l)</td>
<td>7.65$\pm$ (1.52)</td>
<td>7.71$\pm$ (1.62)</td>
<td>21.15$\pm$ (6.71)</td>
</tr>
<tr>
<td>GIP (total) (pg/ml)</td>
<td>207.91$\pm$ (37.76)</td>
<td>180.71$\pm$ (27.53)</td>
<td>114.02$\pm$ (16.92)</td>
</tr>
<tr>
<td>Pancreatic polypeptide (pg/ml)</td>
<td>68.07$\pm$ (6.45)</td>
<td>75.94$\pm$ (6.56)</td>
<td>50.05$\pm$ (2.67)</td>
</tr>
<tr>
<td>Amylin (active) (pg/ml)</td>
<td>358.87$\pm$ (36.12)</td>
<td>364.99$\pm$ (45.07)</td>
<td>504.90$\pm$ (53.34)</td>
</tr>
<tr>
<td>GLP-2 (ng/ml)</td>
<td>0.56$\pm$ (0.06)</td>
<td>0.62$\pm$ (0.04)</td>
<td>0.75$\pm$ (0.05)</td>
</tr>
</tbody>
</table>

Data are mean (SEM). Data with different superscript letters are significantly different at $p<0.05$, according to the post hoc ANOVA statistical analysis.

CT, Cell and Pre, respectively, refer to the selected \textit{ob/ob} mice, fed a normal diet, non-prebiotic control diet or prebiotic diet.

GIP, glucose-dependent insulinopeptidase; GLP, glucagon-like peptide.

![Figure 6](gut.bmj.com)
these data strongly suggest that the modulation of the gut microbiota using prebiotics in obese mice, could act favourably on the intestinal barrier, thereby reducing endotoxaemia, systemic and liver inflammation, with beneficial consequences on associated metabolic disorders.

However, the mechanisms by which prebiotics improve gut permeability – in the particular context of obesity – are not fully understood. One potential explanation could arise from the putative role of the Bifidobacterium spp in maintaining the gut barrier. Interestingly, Bifidobacterium spp do not degrade intestinal mucus glycoproteins like other pathogenic bacteria do, and Bifidobacterium spp promote a healthier microvillus environment by preventing permeability and bacterial translocation. Among the putative mechanisms, it has been demonstrated that the prebiotic modulation of the gut microbiota increases villus height and crypt depth, and leads to a thicker mucosal layer in the jejenum and in the colon. These effects are related to the bacterial fermentation of the prebiotics. The resulting products of fermentation are mainly short-chain fatty acids (SCFAs), with butyrate acting as an energetic substrate for the colonocytes and having a trophic effect on mucosa.

Figure 7 Chronic GLP-2 antagonist treatment blunts prebiotic-induced reduction in endotoxaemia and hepatic inflammatory tone. (A) Plasma LPS concentrations (EU/ml); (B,D) Macrophage infiltration markers: TLR4, CD68 mRNA concentrations; (C,E) oxidative stress markers: NADPHox, iNOS mRNA concentrations; (F,G) hepatic inflammation: PAI-1, TNFα mRNA concentrations; (H) jejunal epithelial tight-junction protein markers (ZO-1 and occludin mRNA) concentrations; (I) jejunal proglucagon mRNA concentrations in ob/ob mice fed a normal diet and injected twice daily with a saline (Ob-CT), prebiotic diet and injected twice daily with a saline (Ob-Pre), prebiotic diet and injected twice daily with GLP-2 antagonist (Ob-Pre-Ant), normal diet and injected twice daily with GLP-2 antagonist (Ob-Ant) for 4 weeks. Data are mean with the SEM. *Significantly different (p<0.05) from Ob-CT and Ob-Pre-Ant according to the Kruskal–Wallis test analysis. Data with different superscript letters are significantly different (p<0.05), according to the post hoc ANOVA statistical analysis. EU, endotoxin unit; GLP-2, glucagon-like protein-2; iNOS, inducible nitric oxide synthase; NADPHox, NADPH oxidase; PAI-1, plasminogen activator inhibitor-1; PG, proglucagon; TJ, tight junction; TLR, toll-like receptor; TNF, tumour necrosis factor.
peptide content) in the proximal colon by a mechanism linked to the differentiation of precursor cells into enteroendocrine cells. In the present study, we additionally found that changing gut microbiota using prebiotics is associated with an increased endogenous production of the glucagon-like peptide-2 (GLP-2). GLP-2 is a 33 amino acid peptide, formed, as GLP-1, from the cleavage of proglucagon peptide. GLP-2 is associated with intestinal growth and adaptation in a variety of pathological conditions, including post-resection intestinal adaptation, coeliac disease, parental nutrition-induced intestinal atrophy and inflammatory bowel disease. In addition, GLP-2 has also been demonstrated to enhance intestinal adaptation and to reduce the internalisation of enteric bacteria in INT-407 enterocytes in vitro model. Strikingly, the intestinotrophic effects observed following prebiotic administration are similar to the physiological effect of GLP-2. The increased GLP-2

Figure 8 Chronic GLP-2 treatment lowers endotoxaemia, improves gut permeability markers, and reduces systemic and hepatic inflammation, oxidative stress and macrophage infiltration markers. (A) Plasma LPS concentrations (EU/ml); Cytokines and chemokines plasma levels (pg/ml): (B) IL1α; (C) IL10; (D) MIP-1α; (E) MCP-1; (F,J) hepatic inflammation: TNFα, PAI-1 mRNA concentrations; (G,I) macrophage infiltration markers: TLR4, CD68 mRNA concentrations; (H,K) oxidative stress markers: iNOS, NADPHox mRNA; (L) immunohistochemistry score and (M) representative immunofluorescence staining of the jejunal epithelial tight-junction proteins (ZO-1 and occludin) measured in ob/ob mice injected twice daily with a saline vehicle (Ob-CT) or GLP-2 (Ob-GLP-2) for 12 days. Data are mean with the SEM. *Significantly different (p < 0.05) from Ob-CT mice according to the two-tailed Student t test. EU, endotoxin unit; GLP-2, glucagon-like protein-2; iNOS, inducible nitric oxide synthase; IL, interleukin; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; NADPHox, NADPH oxidase; TLR, toll-like receptor; TNF, tumour necrosis factor.
production is in accordance with our earlier study, where we found that changing the gut microbiota of rats fed a high-fat diet following a prebiotic treatment, doubled intestinal GLP-2 concentrations.\textsuperscript{46} Besides, here we found that the higher endogenous GLP-2 production is associated with an improvement of the mucosal barrier function, leading to improved tight junctions and decreased plasma LPS concentrations and therefore blunted inflammatory and oxidative stresses. A recent report demonstrates that a chronic treatment with GLP-2 protects rats against the ischaemia–reperfusion-induced endotoxaemia and inflammation, by an unknown mechanism.\textsuperscript{52}

Our first experiment strongly suggests that the lower metabolic endotoxaemia and the consequent low-grade inflammation observed upon prebiotic feeding could be a mechanism involving an enhanced endogenous GLP-2 production. Indeed, we found that Ob-Pre fed mice exhibited a significant increase of plasma GLP-2 levels and that this parameter negatively correlates with markers of gut permeability. Along the same line, we found a positive correlation between intestinal proglucagon and tight-junction proteins mRNA (ZO-1, occludin). Altogether, these data led us to postulate that the prebiotic-induced intestinal proglucagon mRNA expression and the consequent GLP-2 production may positively impact on gut barrier integrity. Therefore, to investigate this hypothesis, we performed a second set of experiments where we treated mice concomitantly with the prebiotic and a GLP-2 antagonist. First, we confirm the improvement of inflammatory markers following the prebiotic treatment; second, and more importantly, we show that the GLP-2 antagonist completely blocks the major features of the prebiotic treatment. Hence, in absence of GLP-2 signalling, the prebiotic treatment failed to reduce plasma LPS levels, and most of the hepatic inflammatory and oxidative stress markers remained equivalent to the control mice. In addition, the GLP-2 antagonist blocks the positive effects of the prebiotic treatment on both intestinal tight-junction proteins and proglucagon mRNA. Altogether, both set of experiments strongly support that specific changes in gut microbiota improve gut permeability and inflammatory tone by a GLP-2 dependent mechanism.

To support the putative therapeutic effect of GLP-2 in the context of a low-grade inflammation associated with obesity, and in order to delineate the protective role of the GLP-2 independently of the modulation of the gut microbiota, we chronically treated mice with GLP-2. This third set of experiment clearly shows that GLP-2 treatment alone significantly lowers inflammatory tone in obese mice. We found that GLP-2 treated mice exhibited a lower metabolic endotoxaemia, and a lower systemic and hepatic inflammatory tone. These features were associated with a strong positive effect of GLP-2 on the tight-junction proteins distribution. This set of experiments demonstrates that GLP-2 can be useful to treat the altered gut barrier observed in obesity and diabetes, and therefore could lower the inflammatory tone associated with these diseases. It would be interesting to see whether the magnitude of those effects is similar in other models such as diet-induced obesity and diabetes (i.e., non-leptin-deficient models).

While the molecular and cellular mechanisms underlying the effect of GLP-2 on the tight junctions and the gut barrier function remained to define, several hypotheses can be postulated. GLP-2 increases the rate of crypt cell proliferation, villus elongation and reduces apoptosis, leading to improved barrier function.\textsuperscript{55} It has been proposed that insulin-like growth factor (IGF)-I acts as an essential target of GLP-2. Recent data have shown that mice lacking IGF-I were resistant to GLP-2-induced intestinal growth, crypt–villus height, and crypt cell proliferation. Furthermore, GLP-2 administration increases intestinal IGF-I secretion in vitro and enhances intestinal IGF-I mRNA transcript levels both in vitro and in vivo.\textsuperscript{56} In addition to this potential mechanism, data suggest that the downstream molecular mechanism by which GLP-2 receptor activation controls barrier function could be related to the activation of the β-catenin signalling pathway.\textsuperscript{57} Nonetheless, further studies are required to fully characterise the mechanisms through which GLP-2 improves gut barrier function.

Together, using the complementary approaches of the specific modulation of the gut microbiota, and of the pharmacological inhibition or activation of the GLP-2 receptor, our findings strongly suggest that GLP-2 participates to the modulation of the gut barrier function and the consequent systemic and hepatic inflammatory phenotype associated with obesity.

In addition, these data demonstrate that a selective modulation of the gut microbiota improves intestinal permeability and inflammatory markers during obesity and diabetes, via an unexpected mechanism such as higher GLP-2 endogenous production.

Thus, we propose that a selective gut microbiota modulation controls and increases endogenous production of the intestinotrophic proglucagon derived peptides GLP-2, and consequently improves gut barrier functions by a GLP-2-dependent mechanism. These new findings demonstrate the usefulness of developing specific therapeutic strategies using GLP-2 to tackle metabolic endotoxaemia and disorders associated with obesity and diabetes, and that gut microbiota modulation could be an interesting tool in this context.

Acknowledgement: We thank RM Goebbel for assistance with the histology.

Funding: PDC is Postdoctoral Researcher from the FRS-FNRS (Fonds de la Recherche Scientifique) Belgium. NMD and PDC are recipients of FSR and FRSM subsidies (Fonds speciaux de recherches, UCL, Belgium; Fonds de la recherché scientifique medicale, Belgium). SP and TVDW are Postdoctoral Researchers from the Research Foundation – Flanders (Fonds voor Wetenschappelijk Onderzoek (FWO) – Vlaanderen).

Competing interests: None.

Ethics approval: Animal experiments were approved by the local ethics committee and housing conditions were as specified by the Belgian Law of 14 November 1993 on the protection of laboratory animals (agreement n° LA 1230314).

REFERENCES

Inflammatory bowel disease


A gastrointestinal cause for heart failure

CLINICAL PRESENTATION
A 67-year-old man presented with worsening shortness of breath on exertion and peripheral oedema of 3 months duration. He had evidence of heart failure including raised jugular venous pressure, gallop rhythm and bilateral pedal oedema. A non-tender liver was palpable about 2–3 cm below the costal margin in the mid-clavicular line. Laboratory investigations revealed iron deficiency anaemia (haemoglobin 250 ng/ml). His serum ferritin was 10 ng/ml (normal range, 15–250 ng/ml). Transthoracic echocardiogram demonstrated evidence of hyperdynamic left ventricle and biventricular failure. Multiple enhancing “lesions” within the liver with enhancement of the hepatic veins and inferior vena cava was evident on the arterial phase of computed tomography of the abdomen (fig 1).

QUESTION
What is your diagnosis?
See page 1128 for the answer.

This case is submitted by:

A Aravinthan, Y Al-naeeb, Z Abubacker, P Richardson
Luton and Dunstable Hospital, Luton, Bedfordshire, UK

Correspondence to: Dr P Richardson, Luton and Dunstable Hospital, Lewsey Road, Luton LU4 0DZ, UK; aaravinthan@doctors.org.uk

Competing interests: None.

Patient consent: Obtained.

Gut 2009;58:1103. doi:10.1136/gut.2008.172536